Cite

HARVARD Citation

    Champion, B. et al. (n.d.). "Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record